APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumonia Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pneumonia Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchPneumonia Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumonia Vaccine Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Pneumonia Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumonia Vaccine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumonia Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Pneumonia Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pneumonia Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumonia Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumonia Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pneumonia Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pneumonia Vaccine include Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc., Zhifei Biologic, Walvax Biotechnology, Serum Institute of India Pvt. Ltd., Sanofi Pasteur and Royal (Wuxi) Bio-Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pneumonia Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumonia Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumonia Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pneumonia Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumonia Vaccine Segment by Company

Johnson & Johnson

Merck & Co., Inc.

Pfizer Inc.

Glaxosmithkline Plc.

Zhifei Biologic

Walvax Biotechnology

Serum Institute of India Pvt. Ltd.

Sanofi Pasteur

Royal (Wuxi) Bio-Pharmaceutical

Emergent Biosolutions

CSL Limited

Astrazeneca Plc.

Astellas Pharma Inc.

Pneumonia Vaccine Segment by Type

Pneumococcal Conjugate Vaccine (PCV13)

Pneumococcal Polysaccharide Vaccine (PPSV23)

Other

Pneumonia Vaccine Segment by Application

Sepsis

Meningitis

Pneumonia

Pneumonia Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumonia Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pneumonia Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pneumonia Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pneumonia Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pneumonia Vaccine Industry Trends Table 2. Pneumonia Vaccine Industry Drivers Table 3. Pneumonia Vaccine Industry Opportunities and Challenges Table 4. Pneumonia Vaccine Industry Restraints Table 5. Global Pneumonia Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pneumonia Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pneumonia Vaccine Sales by Manufacturers (doses) & (2021-2026) Table 8. Global Pneumonia Vaccine Sales Market Share by Manufacturers Table 9. Global Pneumonia Vaccine Average Sales Price (US$/dose) of Manufacturers (2021-2026) Table 10. Global Pneumonia Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pneumonia Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pneumonia Vaccine Manufacturers, Product Type & Application Table 13. Global Pneumonia Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pneumonia Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Pneumococcal Conjugate Vaccine (PCV13) Table 17. Major Manufacturers of Pneumococcal Polysaccharide Vaccine (PPSV23) Table 18. Major Manufacturers of Other Table 19. Global Pneumonia Vaccine Sales by Type 2021 VS 2025 VS 2032 (doses) Table 20. Global Pneumonia Vaccine Sales by Type (2021-2026) & (doses) Table 21. Global Pneumonia Vaccine Sales by Type (2027-2032) & (doses) Table 22. Global Pneumonia Vaccine Sales Market Share by Type (2021-2026) Table 23. Global Pneumonia Vaccine Sales Market Share by Type (2027-2032) Table 24. Global Pneumonia Vaccine Revenue by Type 2021 VS 2025 VS 2032 (doses) Table 25. Global Pneumonia Vaccine Revenue by Type (2021-2026) & (doses) Table 26. Global Pneumonia Vaccine Revenue by Type (2027-2032) & (doses) Table 27. Global Pneumonia Vaccine Revenue Market Share by Type (2021-2026) Table 28. Global Pneumonia Vaccine Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Sepsis Table 30. Major Manufacturers of Meningitis Table 31. Major Manufacturers of Pneumonia Table 32. Global Pneumonia Vaccine Sales by Application 2021 VS 2025 VS 2032 (doses) Table 33. Global Pneumonia Vaccine Sales by Application (2021-2026) & (doses) Table 34. Global Pneumonia Vaccine Sales by Application (2027-2032) & (doses) Table 35. Global Pneumonia Vaccine Sales Market Share by Application (2021-2026) Table 36. Global Pneumonia Vaccine Sales Market Share by Application (2027-2032) Table 37. Global Pneumonia Vaccine Revenue by Application 2021 VS 2025 VS 2032 (doses) Table 38. Global Pneumonia Vaccine Revenue by Application (2021-2026) & (doses) Table 39. Global Pneumonia Vaccine Revenue by Application (2027-2032) & (doses) Table 40. Global Pneumonia Vaccine Revenue Market Share by Application (2021-2026) Table 41. Global Pneumonia Vaccine Revenue Market Share by Application (2027-2032) Table 42. Global Pneumonia Vaccine Sales by Region: 2021 VS 2025 VS 2032 (doses) Table 43. Global Pneumonia Vaccine Sales by Region (2021-2026) & (doses) Table 44. Global Pneumonia Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Pneumonia Vaccine Sales Forecasted by Region (2027-2032) & (doses) Table 46. Global Pneumonia Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Pneumonia Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (doses) Table 48. North America Pneumonia Vaccine Sales by Country (2021-2026) & (doses) Table 49. North America Pneumonia Vaccine Sales by Country (2027-2032) & (doses) Table 50. Europe Pneumonia Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (doses) Table 51. Europe Pneumonia Vaccine Sales by Country (2021-2026) & (doses) Table 52. Europe Pneumonia Vaccine Sales by Country (2027-2032) & (doses) Table 53. Asia Pacific Pneumonia Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (doses) Table 54. Asia Pacific Pneumonia Vaccine Sales by Country (2021-2026) & (doses) Table 55. Asia Pacific Pneumonia Vaccine Sales by Country (2027-2032) & (doses) Table 56. South America, Middle East and Africa Pneumonia Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (doses) Table 57. South America, Middle East and Africa Pneumonia Vaccine Sales by Country (2021-2026) & (doses) Table 58. South America, Middle East and Africa Pneumonia Vaccine Sales by Country (2027-2032) & (doses) Table 59. Global Pneumonia Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Pneumonia Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Pneumonia Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Pneumonia Vaccine Revenue Market Share by Region (2021-2026) Table 63. Global Pneumonia Vaccine Revenue Market Share by Region (2027-2032) Table 64. Johnson & Johnson Company Information Table 65. Johnson & Johnson Business Overview Table 66. Johnson & Johnson Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Johnson & Johnson Pneumonia Vaccine Product Portfolio Table 68. Johnson & Johnson Recent Development Table 69. Merck & Co., Inc. Company Information Table 70. Merck & Co., Inc. Business Overview Table 71. Merck & Co., Inc. Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Merck & Co., Inc. Pneumonia Vaccine Product Portfolio Table 73. Merck & Co., Inc. Recent Development Table 74. Pfizer Inc. Company Information Table 75. Pfizer Inc. Business Overview Table 76. Pfizer Inc. Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Pfizer Inc. Pneumonia Vaccine Product Portfolio Table 78. Pfizer Inc. Recent Development Table 79. Glaxosmithkline Plc. Company Information Table 80. Glaxosmithkline Plc. Business Overview Table 81. Glaxosmithkline Plc. Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolio Table 83. Glaxosmithkline Plc. Recent Development Table 84. Zhifei Biologic Company Information Table 85. Zhifei Biologic Business Overview Table 86. Zhifei Biologic Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Zhifei Biologic Pneumonia Vaccine Product Portfolio Table 88. Zhifei Biologic Recent Development Table 89. Walvax Biotechnology Company Information Table 90. Walvax Biotechnology Business Overview Table 91. Walvax Biotechnology Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Walvax Biotechnology Pneumonia Vaccine Product Portfolio Table 93. Walvax Biotechnology Recent Development Table 94. Serum Institute of India Pvt. Ltd. Company Information Table 95. Serum Institute of India Pvt. Ltd. Business Overview Table 96. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolio Table 98. Serum Institute of India Pvt. Ltd. Recent Development Table 99. Sanofi Pasteur Company Information Table 100. Sanofi Pasteur Business Overview Table 101. Sanofi Pasteur Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Sanofi Pasteur Pneumonia Vaccine Product Portfolio Table 103. Sanofi Pasteur Recent Development Table 104. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 105. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 106. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolio Table 108. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 109. Emergent Biosolutions Company Information Table 110. Emergent Biosolutions Business Overview Table 111. Emergent Biosolutions Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Emergent Biosolutions Pneumonia Vaccine Product Portfolio Table 113. Emergent Biosolutions Recent Development Table 114. CSL Limited Company Information Table 115. CSL Limited Business Overview Table 116. CSL Limited Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. CSL Limited Pneumonia Vaccine Product Portfolio Table 118. CSL Limited Recent Development Table 119. Astrazeneca Plc. Company Information Table 120. Astrazeneca Plc. Business Overview Table 121. Astrazeneca Plc. Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Astrazeneca Plc. Pneumonia Vaccine Product Portfolio Table 123. Astrazeneca Plc. Recent Development Table 124. Astellas Pharma Inc. Company Information Table 125. Astellas Pharma Inc. Business Overview Table 126. Astellas Pharma Inc. Pneumonia Vaccine Sales (doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Astellas Pharma Inc. Pneumonia Vaccine Product Portfolio Table 128. Astellas Pharma Inc. Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Pneumonia Vaccine Distributors List Table 132. Pneumonia Vaccine Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Pneumonia Vaccine Product Image Figure 2. Global Pneumonia Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumonia Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Pneumonia Vaccine Sales (2021-2032) & (doses) Figure 5. Global Pneumonia Vaccine Average Price (US$/dose) & (2021-2032) Figure 6. Global Top 5 and 10 Pneumonia Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Pneumococcal Conjugate Vaccine (PCV13) Image Figure 9. Pneumococcal Polysaccharide Vaccine (PPSV23) Image Figure 10. Other Image Figure 11. Global Pneumonia Vaccine Sales by Type (2021 VS 2025 VS 2032) & (doses) Figure 12. Global Pneumonia Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Pneumonia Vaccine Sales Market Share by Type (2021-2032) Figure 14. Global Pneumonia Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (doses) Figure 15. Global Pneumonia Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Pneumonia Vaccine Revenue Market Share by Type (2021-2032) Figure 17. Sepsis Image Figure 18. Meningitis Image Figure 19. Pneumonia Image Figure 20. Global Pneumonia Vaccine Sales by Application (2021 VS 2025 VS 2032) & (doses) Figure 21. Global Pneumonia Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Pneumonia Vaccine Sales Market Share by Application (2021-2032) Figure 23. Global Pneumonia Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (doses) Figure 24. Global Pneumonia Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Pneumonia Vaccine Revenue Market Share by Application (2021-2032) Figure 26. North America Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 27. North America Pneumonia Vaccine Sales Market Share by Country (2021-2032) Figure 28. U.S. Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 29. Canada Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 30. Mexico Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 31. Europe Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 32. Europe Pneumonia Vaccine Sales Market Share by Country (2021-2032) Figure 33. Germany Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 34. France Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 35. U.K. Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 36. Italy Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 37. Netherlands Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 38. Asia Pacific Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 39. Asia Pacific Pneumonia Vaccine Sales Market Share by Country (2021-2032) Figure 40. China Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 41. Japan Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 42. South Korea Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 43. Southeast Asia Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 44. India Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 45. Australia Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 46. South America, Middle East and Africa Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 47. South America, Middle East and Africa Pneumonia Vaccine Sales Market Share by Country (2021-2032) Figure 48. Brazil Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 49. South Africa Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 50. Saudi Arabia Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 51. Turkey Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 52. Argentina Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 53. UAE Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 54. Egypt Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 55. Chile Pneumonia Vaccine Sales and Growth Rate (2021-2032) & (doses) Figure 56. Global Pneumonia Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Pneumonia Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Pneumonia Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. North America Pneumonia Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Pneumonia Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Europe Pneumonia Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Pneumonia Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Pneumonia Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Pneumonia Vaccine Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Pneumonia Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Pneumonia Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Pneumonia Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Pneumococcal Conjugate Vaccine (PCV13)
  • Pneumococcal Polysaccharide Vaccine (PPSV23)
  • Other
Applications
  • Sepsis
  • Meningitis
  • Pneumonia
Companies covered
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Glaxosmithkline Plc.
  • Zhifei Biologic
  • Walvax Biotechnology
  • Serum Institute of India Pvt. Ltd.
  • Sanofi Pasteur
  • Royal (Wuxi) Bio-Pharmaceutical
  • Emergent Biosolutions
  • CSL Limited
  • Astrazeneca Plc.
  • Astellas Pharma Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pneumonia Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pneumonia Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pneumonia Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pneumonia Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pneumonia Vaccine Market Dynamics
  1. 2.1 Pneumonia Vaccine Industry Trends
  2. 2.2 Pneumonia Vaccine Industry Drivers
  3. 2.3 Pneumonia Vaccine Industry Opportunities and Challenges
  4. 2.4 Pneumonia Vaccine Industry Restraints
3 Pneumonia Vaccine Market by Manufacturers
  1. 3.1 Global Pneumonia Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pneumonia Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pneumonia Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pneumonia Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pneumonia Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pneumonia Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Pneumonia Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pneumonia Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pneumonia Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pneumonia Vaccine Tier 1, Tier 2, and Tier 3
4 Pneumonia Vaccine Market by Type
  1. 4.1 Pneumonia Vaccine Type Introduction
  2. 4.1.1 Pneumococcal Conjugate Vaccine (PCV13)
  3. 4.1.2 Pneumococcal Polysaccharide Vaccine (PPSV23)
  4. 4.1.3 Other
  5. 4.2 Global Pneumonia Vaccine Sales by Type
  6. 4.2.1 Global Pneumonia Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pneumonia Vaccine Sales by Type (2021-2032)
  8. 4.2.3 Global Pneumonia Vaccine Sales Market Share by Type (2021-2032)
  9. 4.3 Global Pneumonia Vaccine Revenue by Type
  10. 4.3.1 Global Pneumonia Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pneumonia Vaccine Revenue by Type (2021-2032)
  12. 4.3.3 Global Pneumonia Vaccine Revenue Market Share by Type (2021-2032)
5 Pneumonia Vaccine Market by Application
  1. 5.1 Pneumonia Vaccine Application Introduction
  2. 5.1.1 Sepsis
  3. 5.1.2 Meningitis
  4. 5.1.3 Pneumonia
  5. 5.2 Global Pneumonia Vaccine Sales by Application
  6. 5.2.1 Global Pneumonia Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pneumonia Vaccine Sales by Application (2021-2032)
  8. 5.2.3 Global Pneumonia Vaccine Sales Market Share by Application (2021-2032)
  9. 5.3 Global Pneumonia Vaccine Revenue by Application
  10. 5.3.1 Global Pneumonia Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pneumonia Vaccine Revenue by Application (2021-2032)
  12. 5.3.3 Global Pneumonia Vaccine Revenue Market Share by Application (2021-2032)
6 Global Pneumonia Vaccine Sales by Region
  1. 6.1 Global Pneumonia Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumonia Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Pneumonia Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Pneumonia Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pneumonia Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pneumonia Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pneumonia Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pneumonia Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pneumonia Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pneumonia Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pneumonia Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pneumonia Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pneumonia Vaccine Revenue by Region
  1. 7.1 Global Pneumonia Vaccine Revenue by Region
  2. 7.1.1 Global Pneumonia Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pneumonia Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Pneumonia Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Pneumonia Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pneumonia Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Pneumonia Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pneumonia Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Pneumonia Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pneumonia Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pneumonia Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pneumonia Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pneumonia Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Pneumonia Vaccine Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Pneumonia Vaccine Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 Pfizer Inc.
  14. 8.3.1 Pfizer Inc. Company Information
  15. 8.3.2 Pfizer Inc. Business Overview
  16. 8.3.3 Pfizer Inc. Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc. Pneumonia Vaccine Product Portfolio
  18. 8.3.5 Pfizer Inc. Recent Developments
  19. 8.4 Glaxosmithkline Plc.
  20. 8.4.1 Glaxosmithkline Plc. Company Information
  21. 8.4.2 Glaxosmithkline Plc. Business Overview
  22. 8.4.3 Glaxosmithkline Plc. Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolio
  24. 8.4.5 Glaxosmithkline Plc. Recent Developments
  25. 8.5 Zhifei Biologic
  26. 8.5.1 Zhifei Biologic Company Information
  27. 8.5.2 Zhifei Biologic Business Overview
  28. 8.5.3 Zhifei Biologic Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Zhifei Biologic Pneumonia Vaccine Product Portfolio
  30. 8.5.5 Zhifei Biologic Recent Developments
  31. 8.6 Walvax Biotechnology
  32. 8.6.1 Walvax Biotechnology Company Information
  33. 8.6.2 Walvax Biotechnology Business Overview
  34. 8.6.3 Walvax Biotechnology Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Walvax Biotechnology Pneumonia Vaccine Product Portfolio
  36. 8.6.5 Walvax Biotechnology Recent Developments
  37. 8.7 Serum Institute of India Pvt. Ltd.
  38. 8.7.1 Serum Institute of India Pvt. Ltd. Company Information
  39. 8.7.2 Serum Institute of India Pvt. Ltd. Business Overview
  40. 8.7.3 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolio
  42. 8.7.5 Serum Institute of India Pvt. Ltd. Recent Developments
  43. 8.8 Sanofi Pasteur
  44. 8.8.1 Sanofi Pasteur Company Information
  45. 8.8.2 Sanofi Pasteur Business Overview
  46. 8.8.3 Sanofi Pasteur Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Pasteur Pneumonia Vaccine Product Portfolio
  48. 8.8.5 Sanofi Pasteur Recent Developments
  49. 8.9 Royal (Wuxi) Bio-Pharmaceutical
  50. 8.9.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  51. 8.9.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  52. 8.9.3 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolio
  54. 8.9.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
  55. 8.10 Emergent Biosolutions
  56. 8.10.1 Emergent Biosolutions Company Information
  57. 8.10.2 Emergent Biosolutions Business Overview
  58. 8.10.3 Emergent Biosolutions Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Emergent Biosolutions Pneumonia Vaccine Product Portfolio
  60. 8.10.5 Emergent Biosolutions Recent Developments
  61. 8.11 CSL Limited
  62. 8.11.1 CSL Limited Company Information
  63. 8.11.2 CSL Limited Business Overview
  64. 8.11.3 CSL Limited Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 CSL Limited Pneumonia Vaccine Product Portfolio
  66. 8.11.5 CSL Limited Recent Developments
  67. 8.12 Astrazeneca Plc.
  68. 8.12.1 Astrazeneca Plc. Company Information
  69. 8.12.2 Astrazeneca Plc. Business Overview
  70. 8.12.3 Astrazeneca Plc. Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Astrazeneca Plc. Pneumonia Vaccine Product Portfolio
  72. 8.12.5 Astrazeneca Plc. Recent Developments
  73. 8.13 Astellas Pharma Inc.
  74. 8.13.1 Astellas Pharma Inc. Company Information
  75. 8.13.2 Astellas Pharma Inc. Business Overview
  76. 8.13.3 Astellas Pharma Inc. Pneumonia Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Astellas Pharma Inc. Pneumonia Vaccine Product Portfolio
  78. 8.13.5 Astellas Pharma Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pneumonia Vaccine Value Chain Analysis
  2. 9.1.1 Pneumonia Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pneumonia Vaccine Production Mode & Process
  6. 9.2 Pneumonia Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pneumonia Vaccine Distributors
  9. 9.2.3 Pneumonia Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst